New acid blocker vonaprazan takes on esomeprazole in reflux healing showdown
NCT ID NCT06953986
First seen Mar 08, 2026 · Last updated Jun 20, 2026 · Updated 18 times
Summary
This study compares two doses of vonaprazan (10 mg and 20 mg) with esomeprazole 40 mg for healing moderate to severe reflux esophagitis (grades B, C, or D) over 8 weeks. About 414 adults with GERD symptoms for at least 4 weeks will be randomly assigned to one of the three groups. The main goal is to see which treatment heals the esophagus better, and researchers will also track symptom improvement and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asian Institute of Gastroenterology /Aig Hospitals
RECRUITINGHyderabad, Telangana, 500082, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vonaprazan (a stomach acid blocker) and esomeprazole (a proton pump inhibitor)
What this could lead to
If successful, vonaprazan could offer a new option for healing severe acid reflux damage, possibly working faster or better than current standard treatments.
What could go wrong
This is a relatively small, early-phase trial without a placebo group, so results may not apply to all patients. Both drugs are already approved for similar uses, so the benefit over existing options may be modest.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.